Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis.
Efinaconazole 10% nail solution is a novel topical antifungal drug for the treatment of onychomycosis. Two Phase III trials were completed using efinaconazole 10% nail solution, where 17.8% and 15.2% of patients achieved complete cure, and 55.2% and 53.4% achieved mycological cure. Several post hoc analyses were carried out using data from Phase III trials to determine the efficacy of efinaconazole with respect to disease duration, disease progression, and comorbidities of diabetes or tinea pedis with onychomycosis. Efinaconazole produced higher efficacy rates with patients presenting onychomycosis in a small portion of the toenail (≤25%) for a shorter duration of time (<1 year and 1-5 years). When patients presenting with both onychomycosis and tinea pedis underwent concurrent treatment, efficacy of efinaconazole increased from 16.1% to 29.4%, suggesting combination therapy improved results. Most interestingly, there was no difference in efinaconazole efficacy between diabetic and non-diabetic groups, indicating efinaconazole could be a safe and effective form of treatment for diabetics. Overall, efinaconazole 10% nail solution shows potential as an antifungal therapy for the treatment of onychomycosis.
Department of Medicine, University of Toronto, Toronto, ON, Canada.
A K
AK
Gupta
Mediprobe Research Inc., London, ON, Canada.
C
C
Studholme
D000287:Administration, Topical; D000935:Antifungal Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D012996:Solutions; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D012996:Solutions; D014230:Triazoles; C431707:efinaconazole